Phoenix is used to analyze the safety and efficacy of drugs under development
PRINCETON, NJ – 2016年7月21日 – Certara®, the leading provider of decision support technology and consulting services for optimizing drug development and improving health outcomes, today announced the appointment of Nathan Teuscher, PhD, to vice president of pharmacometric solutions. In his new role, Dr. Teuscher will lead the company’s Phoenix® software division. He previously served as Certara’s vice president of scientific training.
Dr. Teuscher is the former founder and president of clinical pharmacology consultancy PK/PD Associates, which Certara acquired in Aug. 2015.
“A customer-centric professional, Dr. Teuscher is both a renowned modeler and an accomplished educator in the field of pharmacometrics,” said Certara Chief Executive Officer Edmundo Muniz, MD, PhD. “This appointment will facilitate the Phoenix software platform’s evolution and also support our goal of further engaging the industry about the benefits and usage of modeling and simulation in drug development.”
Dr. Teuscher has held leadership roles in the pharmaceutical industry as a scientist, consultant, and teacher in pharmacokinetics, clinical pharmacology and pharmacometrics. Early in his career, Dr. Teuscher was recognized as a Computerworld Smithsonian Laureate for his work on developing a pioneering web-application to teach pharmacokinetics to pharmacy students at the University of Michigan. Since that time, he has developed many educational tools, including mobile and web applications for pharmacometric analyses.
Phoenix is the pharmaceutical industry’s premier software platform for managing, analyzing and reporting pharmacokinetic (PK), pharmacodynamic (PD), and toxicokinetic data. It is used to analyze the safety and efficacy of drugs under development by pharmaceutical, veterinary and academic researchers, and the US Food and Drug Administration and other global regulatory agencies. Phoenix WinNonlin®, considered the industry’s ‘gold standard’ for non-compartmental analysis, is used by 6,000 researchers in 50 countries.
Certara is a leading decision support technology and consulting organization committed to optimizing drug development and improving health outcomes. Certara’s solutions, which span drug discovery through patient care, use the most scientifically-advanced modeling and simulation technologies and regulatory strategies to increase the probability of regulatory and commercial success. Its clients include hundreds of global biopharmaceutical companies, leading academic institutions, and key regulatory agencies. For more information, visit www.certara.com.
Ellen Leinfuss, 609-216-9586
Chief Marketing Officer
Lisa Osborne, 206-992-5245
Rana Healthcare Solutions